Tech Company Financing Transactions
CinCor Pharma Funding Round
On 5/15/2019, CinCor Pharma raised $50 million in Series A investment from Sofinnova Ventures and 5AM Ventures.
Transaction Overview
Company Name
Announced On
5/15/2019
Transaction Type
Venture Equity
Amount
$50,000,000
Round
Series A
Investors
Sofinnova Ventures (Lead Investor) (James Healy)
Proceeds Purpose
Proceeds from the financing will be used to advance CIN-107 through proof-of-concept Phase 2 clinical trials in these two indications.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
5375 Medpace Way
Cincinnati, OH 45227
USA
Cincinnati, OH 45227
USA
Phone
Undisclosed
Website
Email Address
Overview
CinCor is a clinical-stage biopharmaceutical company with a mission to advance promising clinical candidates toward marketing approval. CinCor's focus is on cardiovascular, metabolic and kidney diseases. CinCor's lead program is CIN-107, a novel aldosterone synthase inhibitor.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Jon Isaacsohn
Chief Operating Officer
Catherine Pearce
VP - Bus. Development
Justin Thompson
VP - Operations
Brendan Doran
Browse more venture capital transactions:
Prev: 5/15/2019: Nextdoor venture capital transaction
Next: 5/15/2019: TomboyX venture capital transaction
Share this article
News on VC Transactions
We do our best to report on every notable VC transaction. VC investment data records reported here are derived from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs